These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

INNOVENT BIO (01801.HK)'s total product revenue for 2024 amounted to more than RMB8.2 billion, representing a robust YoY ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Meanwhile, mazdutide (GCG/GLP-1 dual receptor agonist), teprotumumab (anti-IGF-1R monoclonal antibody), and picankibart (anti-IL-23p19 monoclonal antibody), are currently under review by the ...

Key highlights include: As the company advances key cornerstone products in its pipeline, we are actively expanding the development of mazdutide, teprotumumab, and picankibart into additional ...

Mazdutide is under clinical development by Eli Lilly and Co and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) ...

There is potentially more competition for the incretin giants in the shape of Innovent’s mazdutide (licensed to Lilly for co-development). It’s unlikely to make a dent in the sales figures for the ...

Key highlights include: As the company advances key cornerstone products in its pipeline, we are actively expanding the development of mazdutide, teprotumumab, and picankibart into additional ...